- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07570329
Human Milk Oligosaccharides, Gut Bifidobacterium, Vitamin D, and Infant Immunity (HMO-BIFIDI)
Human Milk Oligosaccharides in Breast Milk and Its Relation to Gut Bifidobacterium, Vitamin D and Immune Modulation in Infants
The goal of this observational study is to learn how certain natural sugar components in breast milk may be linked with vitamin D level, healthy gut bacteria, and immune markers in healthy breastfed infants. The study will include exclusively breastfeeding mothers and their healthy infants aged 1 to 2 months.
The main questions it aims to answer are:
- Is this natural sugar in breast milk linked with the baby's vitamin D level?
- Is this natural sugar in breast milk linked with healthy gut bacteria?
- Is this baby's vitamin D level linked with healthy gut bacteria?
- Is this natural sugar linked with immune factors in breast milk? Participants will answer health questions from questionnaire, undergo a brief physical examination, allow breast milk and a small baby blood sample to be collected, and provide an baby stool sample.
Researchers will test these samples in the laboratory and analyze the results to answer the research questions.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Subject recruitment was conducted during immunization activities at community health centers (Puskesmas) and integrated health posts (Posyandu). The subject collection technique used the quota sampling method, a non-probability subject selection technique carried out by determining the desired sample size (quota) from a population with predetermined criteria, and researchers collected sample units until the target quota was reached. Researchers provided an explanation of the research protocol and obtained informed consent from participants regarding their willingness to participate in the study. Participants who met the eligibility criteria (inclusion and exclusion criteria) were declared as research subjects. Next, a research questionnaire was completed, including recording the subject's identity (mother and baby), the mother's health and nutritional history, childbirth and breastfeeding history, observation of the baby's stool, history and risk factors for allergies, and a general physical examination.
Mature breast milk samples will be analyzed to determine maternal secretion status, HMO status, Bifidobacterium in breast milk, and the status of immune markers such as sCD14, TGF-beta, and IgA in breast milk. Stool samples will be analyzed to determine the infant's intestinal Bifidobacterium. Blood samples will also be analyzed to determine vitamin D levels. Statistical correlations between these parameters will be performed to determine the research objectives.
The collected data is grouped based on the purpose and type of data, then the appropriate statistical method is selected, namely:
- Univariate analysis (Used to describe basic data characteristics, in the form of frequency, mean value, standard deviation, and range)
Bivariate analysis
Comparison Test (To see differences between groups)
- Chi-Square Test → If the variable is categorical (e.g., the relationship between maternal secretory status (Secretory vs. Non-Secretory) and delivery method (Vaginal vs. Cesarean section). An alternative test, the Fisher's Exact test, is performed if the basic assumptions of the Chi-Square are not met.
- T-Test (Independent T-Test) → If you want to compare the means of two groups (e.g., the difference in vitamin D levels between male and female infants). An alternative test, the Mann-Whitney test, is used if the data is not normally distributed.
- ANOVA Test → If you want to compare the means of more than two groups (e.g., the difference in vitamin D levels based on the timing of early breastfeeding initiation: <1 hour, 1-6 hours, >6 hours). An alternative test, the Kruskal-Wallis test, is used if the data is not normally distributed.
Correlation Analysis (To see the relationship between two numeric variables)
- Pearson Correlation → If the data is normally distributed.
- Spearman Correlation → If the data is not normally distributed or is ordinal
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
South Sulawesi
-
Makassar, South Sulawesi, Indonesia, 90245
- Hasanuddin University
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
Maternal Subject :
- Women aged at least 18 years who are physically healthy;
- Have a healthy baby aged 1-2 months with a full-term gestational age (37-42 weeks) and a normal birth weight (2500-4000 grams);
- Exclusively breastfeeding;
- Agree to participate in this study by signing an informed consent form.
Infant Subjects :
- All infants of mothers who meet the inclusion criteria
Exclusion Criteria:
Maternal Subject :
- Currently participating in another clinical trial;
- Having a condition such as a breast abscess or other breast pathology;
- Currently taking medications for conditions that may affect breast milk, such as antibiotics;
- Subjects who cannot comply with the study protocol
Infant Subjects:
- Currently participating in another clinical trial;
- Having a history of antimicrobial treatment (oral or parenteral antibiotics);
- Subjects are unable to comply with the research protocol.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Analysis maternal Human Milk Oligosaccharides (HMO) and Breast Milk (BM) Bifidobacterium and their correlation to gut Bifidobacterium, serum vitamin D and immune regulatory status in infants
Periodo de tiempo: At enrollment (single time point, cross-sectional assessment)
|
This outcome analyze the correlation between maternal human milk oligosaccharide (secretor status, 2FL' level), Breast Milk (BM) Bifidobacterium, gut Bifidobacterium, serum vitamin D and immune regulatory status in infants in infants aged 1 to 2 months.
|
At enrollment (single time point, cross-sectional assessment)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Association between maternal HMO and infant gut Bifidobacterium
Periodo de tiempo: At enrollment (single time point, cross-sectional assessment)
|
Association between maternal human milk oligosaccharide (secretor status and 2FL' level) and Bifidobacterium abundance in infant stool.
|
At enrollment (single time point, cross-sectional assessment)
|
|
Association between maternal HMO and infant vitamin D level
Periodo de tiempo: At enrollment (single time point, cross-sectional assessment)
|
Association between maternal human milk oligosaccharide (secretor status and 2FL' level) and vitamin D level in infant serum.
|
At enrollment (single time point, cross-sectional assessment)
|
|
Association between maternal HMO and breast milk immune markers
Periodo de tiempo: At enrollment (single time point, cross-sectional assessment)
|
This outcome assesses the association between human milk oligosaccharide (HMO) (secretor status and 2FL' level) in breast milk and immune markers in breast milk, including soluble CD14 (sCD14), transforming growth factor beta (TGF-beta), and immunoglobulin A (IgA).
|
At enrollment (single time point, cross-sectional assessment)
|
|
Association between breast milk Bifidobacterium and infant gut microbiota
Periodo de tiempo: At enrollment (single time point, cross-sectional assessment)
|
This outcome assesses the association between Bifidobacterium composition in breast milk and gut microbiota (Bifidobacterium) composition in infant stool samples.
|
At enrollment (single time point, cross-sectional assessment)
|
|
Association between breast milk Bifidobacterium and infant vitamin D level
Periodo de tiempo: At enrollment (single time point, cross-sectional assessment)
|
This outcome assesses the association between Bifidobacterium composition in breast milk and vitamin D level in infant serum.
|
At enrollment (single time point, cross-sectional assessment)
|
|
Association between breast milk Bifidobacterium and breast milk immune marker
Periodo de tiempo: At enrollment (single time point, cross-sectional assessment)
|
This outcome assesses the association between Bifidobacterium composition in breast milk and immune markers in breast milk, including soluble CD14 (sCD14), transforming growth factor beta (TGF-beta), and immunoglobulin A (IgA).
|
At enrollment (single time point, cross-sectional assessment)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Bahrul Fikri, MD, Ph.D, Department of Pediatrics, Faculty of Medicine, Hasanuddin University
- Director de estudio: Andi Raisyiah Akrimah Imran, MD, MHA, Department of Public Health and Family Medicine, Faculty of Medicine, Hasanuddin University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- UH25030200
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .